Greenwich LifeSciences, Inc.
GLSI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001799788
In the last 90 days, Greenwich LifeSciences, Inc. insiders filed 3 open-market purchases and 0 sales; 57 institutions reported holding it in 13F filings for Q2 2026, worth $39.6M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Greenwich LifeSciences, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 28 | 23 | −5 |
| Shares | 827.5K | 628.8K | −198.8K (−24.0%) |
| Value | $11.4M | $6.06M | −$5.35M (−46.9%) |
New holders (1)
Institutions that held Greenwich LifeSciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geneos Wealth Management Inc. | 88 | $849 | 0.00% |
Sold out (6)
Institutions that held Greenwich LifeSciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Marshall Wace, LLP | 43,031 | $593.4K |
| Susquehanna International Group, LLP | 37,100 | $511.6K |
| Jane Street Group, LLC | 18,510 | $255.3K |
| Citigroup Inc | 12,498 | $172.3K |
| 683 Capital Management, LLC | 10,747 | $148.2K |
| Citadel Advisors LLC | 10,354 | $142.8K |